Status:
COMPLETED
The Resting-state EEG Gamma Oscillations in Alzheimer's Disease
Lead Sponsor:
Görsev Yener, MD, PhD
Conditions:
Alzheimer Disease, Early Onset
Eligibility:
All Genders
Up to 65 years
Brief Summary
The literature suggests a strong association between amyloid accumulation and gamma alterations, emerging gamma activity as a biomarker candidate for Alzheimer's pathology. The present study aims to i...
Detailed Description
This cross-sectional study included 24 drug-naive CSF-proven EOAD patients and age-, sex, and education-matched healthy controls. All participants underwent a detailed neuropsychological evaluation, r...
Eligibility Criteria
Inclusion
- For all participants: Age \< 65
- For EOAD patients: Meeting National Institute on Aging-Alzheimer's Association diagnostic criteria.
- For healthy controls: Mini-Mental State Examination (MMSE) \>25 Instrumental Activities of Daily Living Scale (IADL) = 8
Exclusion
- For EOAD patients: MMSE \> 24 Geriatric depression scale (GDS) \> 14 Having treatment with antipsychotics and comorbidities that may affect cognitive abilities.
- For healthy controls: Having neurological and/or cognitive abnormalities Having a history of neurological, psychiatric, or systemic disorders, and alcohol/drug abuse. GDS \> 14
- For all participants: Having neurological (other than AD) or any other serious disease (cancer, systemic disease)
Key Trial Info
Start Date :
November 7 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 5 2019
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT05989087
Start Date
November 7 2012
End Date
April 5 2019
Last Update
August 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
İzmir University of Economics
Izmir, Turkey (Türkiye)